Literature DB >> 3590085

Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.

T Mätzsch, D Bergqvist, U Hedner, P Ostergaard.   

Abstract

A low molecular weight heparin (LMW-heparin) with a mean molecular weight of 4900 dalton was prepared by controlled enzymatic depolymerization of conventional porcine mucosal heparin. The effects of 2,500, 5,000 and 10,000 U (XaI; 29, 58 and 116 mg) on factor Xa inhibition (XaI), factor IIa inhibition (IIaI), APTT, AT III and platelet count were compared to those of 5,000 U (XaI; 26 mg) of conventional heparin given s.c. to 6 healthy volunteers. 5,000 U (XaI; 58 mg) of LMW-heparin was given i.v. A dose related response with regard to the XaI and the IIa-inhibitory activities with peak values at 4 hours after the s.c. injections was obtained. An increase of the XaI/IIaI ratio over the time after injection was seen only after i.v. administration of the LMW-heparin. The APTT was only slightly prolonged and remained within normal range after s.c. injection. AT III and platelet counts were unaffected. The biological half life of the LMW-heparin was 111 minutes if assayed by Xa inhibition, 76 minutes if assayed by IIa inhibition and 40 minutes if assayed by APTT. A strong correlation between the XaI activities obtained and body weight was seen, indicating that LMW-heparin should be administered individually according to body weight.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3590085

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Anticoagulants for venous thrombosis.

Authors:  C H Toh
Journal:  Postgrad Med J       Date:  1997-05       Impact factor: 2.401

Review 3.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 4.  Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.

Authors:  Sheridan M Hoy; Lesley J Scott; Greg L Plosker
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

5.  Heparin in interventional radiology: a therapy in evolution.

Authors:  Stuart B Resnick; Stephanie H Resnick; Joshua L Weintraub; Nishita Kothary
Journal:  Semin Intervent Radiol       Date:  2005-06       Impact factor: 1.513

6.  Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

7.  Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients.

Authors:  Matthew T Rondina; Michelle Wheeler; George M Rodgers; Leslie Draper; Robert C Pendleton
Journal:  Thromb Res       Date:  2009-03-09       Impact factor: 3.944

Review 8.  Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors:  Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

10.  Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme.

Authors:  G Q Liu; G Bengtsson-Olivecrona; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.